Structure and properties of DOTA-chelated radiopharmaceuticals within the225Ac decay pathway-Reference-Cited by-同舟云学术

Structure and properties of DOTA-chelated radiopharmaceuticals within the225Ac decay pathway

Published:2018 Issue:7 Volume:9 Page:1155-1163
ISSN:2040-2503
Container-title:MedChemComm
language:en
Short-container-title:Med. Chem. Commun.

Author:

Khabibullin Artem R.¹²³⁴,Karolak Aleksandra⁵⁶³⁴,Budzevich Mikalai M.⁷⁶³⁴^ORCID,McLaughlin Mark L.⁸⁹¹⁰¹¹⁴,Morse David L.¹²⁶³⁴¹³^ORCID,Woods Lilia M.¹²³⁴^ORCID

Affiliation:

1. Department of Physics

2. University of South Florida

3. Tampa

4. USA

5. Department of Integrated Mathematical Oncology

6. H. Lee Moffitt Cancer Center and Research Institute

7. Small Animal Imaging Laboratory Shared Resource

8. Department of Pharmaceutical Sciences

9. West Virginia University

10. Health Sciences Center

11. Morgantown

12. Department of Cancer Physiology

13. Department of Oncologic Sciences

Abstract

The stability of DOTA-chelated complexes coordinated with H₂O has a strong correlation between the opening angle of DOTA and the atomic mass of the radioactive isotope.

Funder

Basic Energy Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

Pharmaceutical Science,Biochemistry,Drug Discovery,Molecular Medicine,Pharmacology,Organic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/MD/C8MD00170G

Reference60 articles.

1. Radium-223 Therapy of Bone Metastases in Prostate Cancer

2. Active actinium

3. Tumor Therapy with Targeted Atomic Nanogenerators

4. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer;EJNMMI Radiopharmacy and Chemistry;2024-08-24

2. Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review;Pharmaceuticals;2024-03-04

3. Alpha-Emitting Radionuclides: Current Status and Future Perspectives;Pharmaceuticals;2024-01-08

4. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides;Chemical Reviews;2023-10-05

5. LC–MS/MS Bioanalysis of Radioligand Therapeutic Drug Candidate for Preclinical Toxicokinetic Assessment;Analytical Chemistry;2023-07-04